U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer
09 oct. 2012 08h00 HE
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
Laurantis Pharma Completes Funding Round for Research Program
04 sept. 2012 07h59 HE
|
Laurantis Pharma OY
BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
U.S. Patent Office Allows Laurantis Application for Treatment of Skin Inflammation
01 août 2012 08h00 HE
|
Laurantis Pharma Oy
TURKU, FINLAND--(Marketwire - Aug 1, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) as it pertains to the topical...
Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study
28 juin 2012 10h03 HE
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Jun 28, 2012) - Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to...
MEDIA ADVISORY: Speaker Lineup Unveiled for National HIV Testing Day Press Conference; Representatives, HIV Advocates to Take the Test, Spotlight Ryan White Funding, Affordable Care Act and More
26 juin 2012 07h00 HE
|
National Association of People with AIDS
WASHINGTON, DC--(Marketwire - Jun 26, 2012) - The National Association of People with AIDS (NAPWA) and OraSure Technologies, Inc. (NASDAQ: OSUR) announced an expected lineup of speakers who...
International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5
07 juin 2012 07h01 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine...
International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
07 juin 2012 07h00 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
The new patent filed 6 June aims to strengthen the Company's general protection of its...
First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin
29 mai 2012 11h22 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 29, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
Open, clinical study, dose escalating, phase I/II, with Bionor...
Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting
11 mai 2012 08h52 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine
10 mai 2012 06h47 HE
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Vaccine related immune responses found in HIV patients given Vacc-4x...